CaaMTech Synthesizes 3 More Psilocybin Alternatives
Frontiers | Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
MicroRNA-206 suppresses mesothelioma progression via the Ras signaling axis: Molecular Therapy - Nucleic Acids
Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities | Journal of Medicinal Chemistry
4-acetoxy DMT (fumarate) (4-acetoxy-N,N-Dimethyltryptamine, O-Acetylpsilocin, Psilacetin, CAS Number: 1217230-42-6) | Cayman Chemical
Breztri Aerosphere Phase III trial meets primary endpoints
4-hydroxy MET (4-HO MET, Metocin, CAS Number: 77872-41-4) | Cayman Chemical
Psilacetin derivatives: fumarate salts of the methyl–ethyl, methyl–allyl and diallyl variants of the psilocin prodrug - ScienceDirect
Clinical Policy: Monomethyl Fumarate (Bafiertam)
PHARMACY POLICY STATEMENT
4-Acetoxy-N-methyl-N-ethyltryptamine Fumarate (4-AcO-MET Fumarate; 4-Acetoxy-MET Fumarate), 10 mg
Clinical Policy: Dimethyl fumarate (Tecfidera)
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study | Respiratory Research | Full Text
Prior Authorization - Multiple Sclerosis – Vumerity® (diroximel fumarate delayed-release capsules)
Qmx Laboratories - 4-AcO-METFumarate
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis
Fumarate Hydratase-Deficient Renal Cell Carcinoma
CRITERIA FOR DRUG COVERAGE Tenofovir alafenamide (Vemlidy)
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials - The Lancet
Cancers | Free Full-Text | Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer
RCSB PDB Group Summary: 910_30
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications | Oncogene
ANALYTICAL REPORT1
